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Factors associated with growth disturbance
at celiac disease diagnosis in children: A
retrospective cohort study
Samuli Nurminen1,2, Laura Kivelä1,2, Juha Taavela2, Heini Huhtala3, Markku Mäki2, Katri Kaukinen1,4
and Kalle Kurppa1,2*
Abstract
Background: Impaired growth is a well-known complication in celiac disease, but factors associated with it are
poorly known. We investigated this issue in a large cohort of children.
Methods: 530 children with biopsy-proven celiac disease were included. The participants were divided into two
groups on the basis of the presence (n = 182) or absence (n = 348) of growth disturbance at diagnosis. Histological,
serological and clinical characteristics were compared between children with growth failure and those with normal
growth. Further, patients with growth failure as the sole clinical presentation were compared to those with poor
growth and concomitant other symptoms.
Results: Children with growth failure were younger (p < 0.001) and had lower hemoglobin (p = 0.016) and higher
celiac antibody (p < 0.001), alanine aminotransferase (p = 0.035) and thyroid-stimulating hormone values (p = 0.013)
than those with normal growth. Significantly associated with growth failure at diagnosis were age <3 years (OR 4.3
(95 % CI 2.5-7.5) vs older age), diagnosis before the year 2000 and in 2000–09 (OR 3.1 (1.8-5.4) and OR 1.8 (1.1-2.8)
vs diagnosis in 2010–2013), presence of total and subtotal villous atrophy (OR 4.2 (2.5-7.0) and OR 2.0 (1.3-3.2) vs
partial atrophy), severe symptoms (OR 3.4 (1.8-6.7) vs mild symptoms) and vomiting (OR 3.1 (1.5-6.3). The presence
of abdominal pain reduced the risk (OR 0.5 (0.3-0.7)), while there was no effect of gender, diarrhea, constipation,
other chronic diseases and celiac disease in the family. Children evincing poor growth as the sole clinical
presentation were older (p < 0.001) and had higher hemoglobin (P < 0.001) and total iron (p = 0.010) values and
lower TG2ab values (p = 0.009) than those with growth disturbance and other symptoms.
Conclusions: In particular young age and severe clinical and histological presentation were associated with growth
disturbance at celiac disease diagnosis. Children with only poor growth are markedly different from those with
other concomitant symptoms, suggesting different pathogenic mechanisms.
Keywords: Celiac disease, Children, Growth failure
Background
Population-based screening studies have revealed celiac
disease to be a very common health problem with a
true prevalence of up to 3 % in children [1]. Besides the
classical gastrointestinal symptoms, diarrhea and mal-
absorption, the condition may present with various
extraintestinal manifestations [2]. A frequent, and
sometimes the only clinical presentation is impaired
growth [3, 4]. Despite being a long-recognized sign of
the disease the pathophysiology and factors accom-
panying growth failure in celiac disease remain some-
what obscure. Traditionally the poor growth has been
attributed to severe histological damage leading to
malabsorption of essential nutrients, but the actual
evidence for this is scant [5]. Other proposed mecha-
nisms are for example abnormalities in the growth
hormone/insulin-like growth factor-1 axis [6–8] and
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increased prevalence of anti-pituitary antibodies [9].
Regardless of the cause, after the commencement of a
gluten-free diet significant catch-up growth usually
follows [10]. However, in particular in those diagnosed
in later childhood this may remain incomplete, leading
possibly to reduced adult height [10], though this as-
pect remains controversial [11, 12]. The heterogeneous
clinical picture of celiac disease makes it difficult to
recognize and predisposes to long diagnostic delay [13],
further increasing the risk of permanent growth failure.
In order to prevent this complication it would be im-
portant to better understand the factors associated
with poor growth in celiac disease.
In Finland celiac disease is common, and there have
been nationwide guidelines for its diagnosis and treat-
ment since the end of the 1990s [14]. A major aim of
the regularly updated guidelines is early diagnosis and
subsequent prevention of the possible severe compli-
cations, including poor growth in childhood. We here
investigated the prevalence and associated factors in
growth disturbance in pediatric celiac disease in the
era of the modern diagnostic approach.
Methods
Patients and data collection
The study was conducted at the Tampere Center for
Child Health Research, University of Tampere and
Tampere University Hospital. The study cohort com-
prised 530 children (age under 16 years at diagnosis)
with biopsy-proven celiac disease collected in our regu-
larly updated pediatric research database. The patient
information was either updated prospectively or col-
lected from the medical records and, if incomplete,
later supplemented with personal or parents’ interviews
by a study nurse with expertise in celiac disease. The
following information was gathered from all study
subjects: demographic and anthropometric data, year of
the celiac disease diagnosis, clinical presentation at
diagnosis, values of serum celiac disease-specific anti-
bodies and various laboratory parameters, severity of
small-bowel mucosal damage and presence of either
known celiac disease-associated or other concomitant
chronic disease (e.g. type 1 diabetes mellitus, auto-
immune thyroidal disease, asthma, allergies) and celiac
disease in the family. After the analyses the children
were divided into subjects with poor growth and those
with normal growth prior to the celiac disease diagno-
sis (see below in detail).
Clinical symptoms
The severity of the clinical presentation at celiac disease
diagnosis was further classified into four categories as
follows: no symptoms (asymptomatic screen-detected
subjects), mild symptoms (occasionally disturbing
gastrointestinal or extraintestinal symptoms), moderate
symptoms (multiple or more disturbing or frequent symp-
toms) and severe symptoms (symptoms seriously disturbing
normal life; e.g. continuous symptoms or night awakenings
due to the symptoms). Gastrointestinal symptoms were
sub-categorized into diarrhea, abdominal pain, constipation
and vomiting.
Serology and laboratory parameters
In our hospital the serum transglutaminase 2 (TG2ab)
antibodies are measured using automatized human
recombinant-based EliA assay (Phadia AB, Uppsala,
Sweden). A TG2ab value of 7 U/l or higher is considered
positive and the maximum reported value is 120 U/l.
Serum endomysial antibodies (EmA) are measured in
our research center by an indirect immunofluorescence-
based in-house method using human umbilical cord as
substrate [15]. An EmA dilution of 1:≥5 is considered
positive and positive sera are further diluted from 1:50
to 1:4000.
The following laboratory values were collected from
each child at diagnosis when available: blood hemoglobin
(g/l), serum total iron (μmol/l), the mean corpuscular
volume (MCV) (fl), serum alkaline phosphatase (U/l),
serum alanine aminotransferase (ALT) (U/l), serum albu-
min (g/l), serum thyroid-stimulating hormone (TSH)
(mU/l) and serum thyroxin (pmol/l). Anemia at diagnosis
was defined as a blood hemoglobin value lower than that
of the age- and gender-specific reference in the local
hospital laboratory.
Small-bowel mucosal morphology
In our clinical practice a minimum of four duodenal
samples are taken upon upper gastrointestinal endos-
copy in all cases of celiac disease suspicion. The biopsies
are passed to the pathology unit, where they are proc-
essed and analyzed. Only correctly oriented specimens
are accepted for further microscopic analyses [16]. The
severity of small-bowel mucosal villous atrophy here was
categorized based on the hospital pathologist’s original
grading into partial (PVA), subtotal (SVA) and total
villous atrophy (TVA). These correspond approximately
to Marsh-Oberhuber grades IIIa, IIIb and IIIc.
Growth parameters
Height-for-age was expressed in standard deviation
(SD) units, which compare the height of a child to the
average height of Finnish children of the same age [17].
Poor growth was defined as an abnormal deceleration of
growth development compared with age- and gender-
specific reference values or growth below the of expected
target height based on the mean of parental heights [18].
The expected growth rate was considered abnormally
low if the current height differed from the expected
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more than −2.3 SD. If the parental heights were not
known, the child’s height was allowed to differ a max-
imum of −2.7 SD from the age- and sex-based refer-
ence [17]. In most cases the presence of poor growth
was defined by the physician referring the patient for
further endoscopic investigations. The weight of the
children was expressed as weight-for-height percent-
age, as age- and gender-matched SD units and as
body mass index (BMI, kg/m2).
Ethical aspects
Collection of the medical records and patient inter-
views were approved by the Department of Pediatrics,
Tampere University Hospital and by the Ethics Com-
mittee of the Pirkanmaa Hospital District, Tampere,
Finland. Written informed consent was obtained from
all patients and/or their parents participating in the
personal interviews.
Statistical analysis
Statistical analyses were performed using Statistical
Package for the Social Sciences (SPSS) statistical soft-
ware (SPSS Inc., Chicago, IL, USA). In Tables 1 and 4
the data are expressed either in medians with upper and
lower quartiles (Q1, Q3) or as percentages and differ-
ences between the growth failure and normal growth
groups were compared with Mann–Whitney U test or
Chi square test. In Tables 2 and 3 the relative risk of
growth failure is expressed using odds ratios with 95 %
confidence intervals. A P value < 0.05 was considered
statistically significant.
Results
Altogether 182 (34 %) children presented with disturbed
growth and 348 (66 %) with normal growth at celiac
diagnosis. Children with poor growth were significantly
younger and had by definition lower median height but
also lower weight parameters compared with those with
normal growth (Table 1). There was also a trend towards
later onset of menarche in girls with growth failure, but
this was not significant (Table 1).
Serum EmA and TG2ab values were significantly
higher in the growth failure group than in the normal
growth group at diagnosis (Table 1). Further, median
hemoglobin was significantly lower and ALT and TSH
higher in children with poor growth. TSH was above
the reference in 4 children with growth disturbance
and in 2 with normal growth; however, none of these
6 had TSH values >10 mU/l or other clinical signs of
hypothyroidism such as fatigue, increasing weight or
weakness. No differences in thyroxin values or other
laboratory parameters were observed between the groups
(Table 1). Previously diagnosed concomitant thyroid
disease under treatment was noted in 7 (4.1 %) children
Table 1 Baseline characteristics in 530 children with or without growth failure before celiac disease diagnosis
Growth failure n = 182 Normal growth n = 348
na Median (Q1, Q3) n
a Median (Q1, Q3) P value
Age at diagnosis, yr 182 6.3 (2.5, 11.7) 348 8.0 (5.0, 12.0) <0.001
Age of menarche, yr 23 13.0 (12.0, 13.0) 45 12.0 (12.0, 13.0) 0.146
Height, SDb 45 −0.5 (−1.2, 0.4) 134 0.2 (−0.5, 0.9) 0.004
Weight, SD 34 −1.1 (−1.9, −0.2) 114 −0.3 (−0.9, 0.6) 0.003
Weight/height percentage 65 −9.0 (−15.0, −1.0) 163 0.1 (−8.0, 9.0) <0.001
Body mass index, kg/m2 68 15.7 (14.3, 16.6) 155 16.6 (15.1, 19.2) <0.001
EmA, titer 81 500 (200, 2000) 205 200 (100, 1000) <0.001
TG2ab, U/lc 98 120.0 (71.3, 120.0) 253 120.0 (39.0, 120.0) 0.035
Hemoglobin, g/l 129 122 (115, 128) 248 126 (115, 133) 0.016
MCV, fl 96 81 (75, 83) 207 81 (76, 83) 0.662
Alkaline phosphatase, U/l 42 309 (148, 511) 79 231 (184, 322) 0.180
ALT, U/l 34 24 (18, 32) 83 20 (16, 25) 0.035
Total iron, μmol/l 33 10.0 (6.6, 15.0) 58 12.5 (9.3, 17.8) 0.304
Albumin, g/l 18 37 (34, 41) 50 39 (37, 41) 0.252
TSH, mU/l 43 2.8 (2.2, 3.7) 58 2.4 (1.6, 3.1) 0.013
Thyroxin, pmol/l 31 14.4 (12.6, 16.9) 25 14.8 (12.9, 16.3) 0.817
Q1, Q3, lower and upper quartiles; SD, standard deviation; EmA, endomysial antibodies; TG2ab, transglutaminase 2 antibodies; MCV, mean corpuscular volume;
ALT, alanine aminotransferase; TSH, thyroid stimulating hormone
aData available
bIncludes only measurements made by a pediatrician at the time of gastrointestinal endoscopy
cUpper limit of the assay 120.0 U/l
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with poor growth and 6 (1.7 %) with normal growth
(p = 0.102).
Among the demographic and clinical characteristics
significantly associated with growth disturbance at celiac
disease diagnosis was age below three years compared
with older age and celiac disease diagnosis before the
year 2010 compared with the later era (Table 2). There
was no association between growth failure and gender,
presence of any other concomitant chronic disease or
presence of celiac disease in the family (Table 2).
A significant association was seen between abnormal
growth and the presence of subtotal and total small-
bowel mucosal villous atrophy (Table 3). Of symptoms
overall the presence of in general severe symptoms and
of specific gastrointestinal symptoms vomiting increased
the risk of poor growth. In contrast, abdominal pain
reduced the risk, whereas the presence of diarrhea,
constipation and anemia had no effect (Table 3).
In a separate analysis among the 182 children with
growth failure this was the sole clinical presentation of
celiac disease in 46 (25 %) subjects at diagnosis, while
the remaining 136 (75 %) also had other clinical symp-
toms (Table 4). Children with poor growth as the sole
manifestation were significantly older and had higher
hemoglobin, MCV and total iron values and lower
TG2ab values than those with other concomitant symp-
toms, while there were no significant differences be-
tween the groups in the other study variables (Table 4).
Discussion
The present study demonstrated that children with poor
growth at celiac disease diagnosis are significantly younger
Table 2 Association between clinical characteristics and growth disturbance at diagnosis in 530 children with celiac disease
na Growth failure, % Odds ratio 95 % CI P value
Gender
Boys 194 33.5 1
Girls 336 34.8 1.06 0.73 - 1.54 0.759
Age at diagnosis, years
<3 74 66.2 4.32 2.49 - 7.48 <0.001
3-7 203 26.6 0.80 0.53 - 1.20 0.281
8-17 253 31.2 1
Year of diagnosis
<2000 114 48.2 3.11 1.82 - 5.35 <0.001
2000-09 277 34.3 1.75 1.10 - 2.78 0.019
2010-13 139 23.0 1
Type 1 diabetes mellitus
No 475 33.7 1
Yes 41 24.4 0.64 0.30 - 1.33 0.228
Thyroid disease
No 502 32 1
Yes 13 54 2.45 0.81 - 7.40 0.113
No 474 32.9 1
Yes 42 33.3 1.02 0.52 - 1.99 0.956
History of allergy
No 393 34.9 1
Yes 125 28.0 0.73 0.47 - 1.13 0.157
Other concomitant chronic diseaseb
No 202 29.7 1
Yes 315 35.6 1.31 0.89 - 1.91 0.169
First-degree relative with celiac disease
No 157 35.7 1
Yes 140 26.4 0.65 0.39 - 1.07 0.087
aData available
bE.g. epilepsy, rheumatoid arthritis, psychiatric disorder, inflammatory bowel disease, congenital heart disease, immune deficiency
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and have more severe disease in terms of symptoms,
serology and histological damage compared with those
with normal growth. It was also shown that the risk of
growth failure has decreased during the past few decades,
and that children with growth failure as the sole presenta-
tion are markedly different from those with concomitant
other symptoms.
The association between histology and growth was
demonstrated by the more frequent observation of poor
growth in children with subtotal or total villous atrophy
compared with those with partial atrophy. Although a
seemingly logical finding, there is a surprising scarcity of
studies touching upon this issue, and the few conducted
have shown no clear relationship [19, 21, 22]. This dis-
crepancy between the present and earlier results might be
explained by the smaller numbers of patients in previous
studies and variable definitions of growth failure. Weiz-
man and colleagues [19] also speculated that the extent of
mucosal damage might be more related to poor growth in
celiac disease than the degree of atrophy; this is however,
contradicted by evidence that the extent of enteropathy
does correlate with clinical presentation [22]. Our findings
support the role of villous atrophy and malabsorption of
essential nutrients as an important cause of decreased
growth in celiac disease. In accord with this was the obser-
vation of lower weight and hemoglobin values in the
growth failure group. Similarly, even though still mostly at
normal level, the ALT values were significantly higher level
in children with poor growth, again indicating more ad-
vanced disease.
Here children with poor growth had significantly
higher celiac antibody levels at diagnosis than those with
normal growth. Previously Bingley and colleagues [23]
have shown EmA-positive children to be shorter and
lighter than corresponding seronegative non-celiac chil-
dren. To our knowledge, however, the difference in
serology noted here in children with celiac disease has
not been reported before. The finding is in accord with
the previously shown association between higher anti-
body levels and more severe histological and clinical
presentation [20, 24, 25]. The correlation between ser-
ology and poor growth might thus in fact be a result of
more severe mucosal damage, but it is also possible that
the antibodies have a direct role in the disease pathogen-
esis [26].
The presence of growth failure was also associated
with generally more severe gastrointestinal symptoms.
Of specific symptoms vomiting increased the risk, while
diarrhea, somewhat unexpectedly, did not. In contrast,
the presence of the “non-classical” symptom abdominal
pain in fact reduced the risk. Severity of gastrointestinal
symptoms has previously been linked with more
advanced villous atrophy in some studies [19, 24] but
not in others [27, 28]. Interestingly, adult celiac disease
patients with diarrhea were recently shown to have less
severe villous atrophy than those with anemia [29].
Although in that study the possible confounding diseases
such as microscopic colitis were not systemically
excluded, it nicely demonstrates the complicated rela-
tionship between clinical and histological presentation in
celiac disease. It is also possible to have growth-disturbing
protein-losing enteropathy without diarrhea [30]. The
protective effect of abdominal pain might be ex-
plained for example by less severe villous atrophy in
these subjects. Obviously more studies are needed to
decipher the mechanisms behind the multifaceted
clinical picture in celiac disease.
Children with poor growth were almost two years youn-
ger than those with normal growth, and at particular risk
were those below three years at diagnosis. Similar results
have previously been reported from Sweden [31]. These
findings suggest that the rapid growth during infancy
is particularly vulnerable to malabsorption caused by
untreated celiac disease. Conversely, it is possible that
Table 3 Association between histologic and symptomatic
presentation and growth disturbance
na Growth failure, % Odds ratio 95 % CI P value
Degree of small-bowel mucosal villous atrophy
Partial 174 20.7 1
Subtotal 194 34.5 2.02 1.26 - 3.24 0.003
Total 126 52.4 4.22 2.54 - 7.00 <0.001
Severity of symptomsb
Mild 258 28.7 1
Moderate 107 35.5 1.37 0.85 - 2.21 0.198
Severe 43 58.1 3.45 1.78 - 6.70 <0.001
Asymptomatic 121 37.2 1.47 0.93 - 2.33 0.097
Diarrhea
No 319 32.3 1
Yes 181 37.6 1.26 0.86 - 1.85 0.232
Abdominal pain
No 267 42.7 1
Yes 230 25.7 0.46 0.32 - 0.68 <0.001
Constipation
No 425 35.8 1
Yes 72 26.4 0.64 0.37 - 1.13 0.124
Vomiting
No 466 32.4 1
Yes 32 59.4 3.05 1.47 - 6.34 0.003
Anemia
No 420 32.4 1
Yes 91 37.4 1.25 0.78 - 2.00 0.361
aData available
bGrowth failure was not considered as a symptom here at diagnosis in 530
children with celiac disease
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toddlers with poor growth as a presenting symptom are
diagnosed earlier since they are regularly followed in child
welfare clinics. Interestingly, children with growth failure
as the sole presentation were significantly older than those
with concomitant other symptoms. There could be differ-
ent pathophysiological mechanisms present, and it has
indeed been speculated that poor growth in children with
classical symptoms is caused by malabsorption and in
those with atypical presentation by abnormalities in the
growth hormone-insulin-like growth factor axis [6–8, 32].
Also, as presumed in Crohn’s disease [33, 34], muco-
sal inflammation may directly contribute to abnormal
growth. Because of the increased risk of growth hor-
mone deficiency, there should be low threshold for
endocrinological evaluation in children with no sig-
nificant catch-up growth after one year on a gluten-
free diet.
Interestingly, the TSH values here were higher in the
growth failure group. Children with celiac disease are
known to be at increased risk of autoimmune thyroid
diseases [34]. This notwithstanding, only four children
with growth failure had TSH values above the reference
and none of them had other hypothyreosis symptoms or
values usually required for such a diagnosis [35]. It is still
possible that subclinical hypothyreosis had an exacerbat-
ing effect on the poor growth, but currently it remains
controversial whether these children would benefit from
hormone replacement therapy [36]. In any case, it is im-
portant to remember the possibility of associated thyroid
disease in poorly growing children with celiac disease.
The finding that risk of growth failure was decreased
over time is in line with other recent reports [4, 31, 37]
and very likely reflects earlier diagnosis due to increased
awareness and improved diagnostic tools. We found a
higher prevalence of poor growth than previously
reported by Savilahti and colleagues [4] but lower than
that reported by group under Rashid [38]. These dis-
crepancies might be explained by differences in defin-
ition, as growth failure has often been defined as a
height below −2 SD compared with the reference popu-
lation (“short stature”) [4], whereas we defined it as ei-
ther height below the expected target or abnormal
deflection of the growth. The latter method has proved ef-
fective and may allow indentification children with celiac
disease earlier and thus reduce the risk of permanent
growth failure [19, 39]. In contrast, short stature as such is
often only a normal variant and thus not a particularly re-
liable marker for true growth abnormality [40].
The strengths of this study were its large size and
well-defined celiac disease diagnoses. We also had a
wide range of clinically relevant data on each patient.
Nevertheless, in particular laboratory values were lack-
ing in a substantial part of the study subjects. Another
limitation was that, although proved appropriate, the
definition of growth failure used here might limit
generalization of the results. Finally, since growth hor-
mone metabolism or other endocrinological factors
possibly implicated were not investigated here, we
cannot verify the mechanisms underlying poor growth,
this being an issue for future studies.
Table 4 Comparison of baseline data between celiac children with poor growth as sole clinical presentation and those with other
concomitant symptoms
na Poor growth as only symptom n = 46 na Poor growth with other symptoms n = 136 P value
Age at dg, median, yr 46 11.5 (7.4, 13.1) 136 5.0 (2.0, 10.0) <0.001
Girls, % 46 54 136 67 0.104
Anemia, % 40 15 130 22 0.085
Degree of villous atrophy, % 0.449
Partial 10 23 26 21
Subtotal 14 32 53 42
Total 20 45 46 37
Body mass index, kg/m2 24 15.5 (14.3, 17.0) 44 15.8 (14.3, 16.5) 0.847
Hemoglobin, g/l 28 128 (123, 135) 101 120 (110, 127) <0.001
MCV, fl 23 82 (78, 85) 73 79 (74, 83) 0.039
Alkaline phosphatase 10 284 (119, 640) 32 320 (148, 511) 0.859
Total iron, μmol/l 8 19.5 (9.9, 34.2) 25 7.5 (5.6, 14.2) 0.010
TSH, mU/l 12 3.1 (1.8, 3.8) 31 2.7 (2.0, 3.6) 0.684
Thyroxin, pmol/l 8 15.9 (14.3, 18.1) 23 14.2 (12.5, 16.4) 0.298
EmA, titer 26 500 (200, 1250) 81 1000 (200, 4000) 0.516
TG2ab, U/l 31 120 (30, 120) 67 120 (95, 120) 0.009
aData available
SD, standard deviation; MCV, mean corpuscular volume; TSH, thyroid stimulating hormone; EmA, endomysial antibodies; TG2ab, transglutaminase 2 antibodies
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Conclusions
To conclude, our results demonstrate that growth failure
in symptomatic children with celiac disease is associated
in particular with young age and severe presentation at
diagnosis. Differences between children having poor
growth as the sole clinical presentation and those with
concomitant other symptoms indicate that there are
different underlying mechanisms.
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